SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-22-081472
Filing Date
2022-12-20
Accepted
2022-12-20 17:29:57
Documents
7
Period of Report
2022-12-20

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea170536-6k_biondvax.htm 6-K 20182
2 UNDERWRITING AGREEMENT, DATED DECEMBER 16, 2022, BETWEEN THE COMPANY AND AEGIS C ea170536ex1-1_biondvax.htm EX-1.1 220009
3 FORM OF PRE-FUNDED WARRANT ea170536ex4-1_biondvax.htm EX-4.1 119071
4 FORM OF EXCHANGEABLE WARRANT ea170536ex4-2_biondvax.htm EX-4.2 99873
5 FORM OF NON-EXCHANGEABLE WARRANT ea170536ex4-3_biondvax.htm EX-4.3 104334
6 PRESS RELEASE DATED DECEMBER 20, 2022 ea170536ex99-1_biondvax.htm EX-99.1 13253
7 GRAPHIC ex99-1_001.jpg GRAPHIC 6158
  Complete submission text file 0001213900-22-081472.txt   586438
Mailing Address JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM L3 00000
Business Address JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM L3 00000 972-8-9302529
BiondVax Pharmaceuticals Ltd. (Filer) CIK: 0001611747 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-37353 | Film No.: 221475884
SIC: 2836 Biological Products, (No Diagnostic Substances)